Knockout of PKCδ repressed DLBCL cell proliferation, facilitated cell cycle arrest in the G2/M phase, induced apoptosis in vitro, and inhibited tumor growth in vivo, and enhanced sensitivity to rituximab and chemotherapeutics. This evidence concerns the gene PRKCD and diffuse large B-cell lymphoma.